NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04270409 2025-12-12
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
Phase 3 Active not recruiting
NCT06209606 2024-12-17
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
Phase EARLY_PHASE1 Recruiting
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT03110822 2023-11-01
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Oncotherapeutics
Phase 1 Recruiting
NCT04519476 2023-10-31
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
Phase 1 Unknown
NCT01985126 2018-06-25
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
Janssen Research & Development, LLC
Phase 2 Completed
NCT00574288 2018-04-27
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed